文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

替诺福韦二吡呋酯/恩曲他滨与多西环素每日双联HIV及性传播感染暴露前预防的随机对照先导试验:DuDHS研究

A Pilot, Randomized Controlled Trial of Dual Daily HIV and Sexually Transmitted Infection Pre-exposure Prophylaxis Using Tenofovir Disoproxil Fumarate/Emtricitabine and Doxycycline in Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women: The DuDHS Study.
PubMed 文献 · Clin Infect Dis · 2026-01-01

在52名有梅毒史、无HIV感染的性活跃男男性行为者和跨性别女性中,每日TDF/FTC基础上随机分为即日开始或24周后开始每日多西环素暴露前预防,48周时自报依从性两组无显著差异,无多西环素暴露前预防相关严重不良事件,多西环素使用与性传播感染减少相关(aOR 0.36;95%CI:0.15-0.89),即日组发现5例、延迟组1例新发多西环素耐药金黄色葡萄球菌(P=0.077),作者认为双联暴露前预防可行且需进一步评估给药策略、疗效与耐药影响。

要点

  • 即日组与延迟组48周自报TDF/FTC依从性(≥95%)为75.0%对66.7%(P=0.538),多西环素为70.8%对61.9%(P=0.526)。
  • 48周内使用多西环素(对比未使用,即延迟组前24周)与性传播感染减少相关(aOR 0.36;95%CI:0.15-0.89)。
  • 即日组5例、延迟组1例检出新发多西环素耐药金黄色葡萄球菌(P=0.077),无多西环素暴露前预防相关严重不良事件。

核心结论

  • 每日多西环素联合TDF/FTC的双联HIV/性传播感染暴露前预防可行,且与性传播感染发病显著减少相关;作者认为需进一步评估给药策略、疗效及对抗菌药物耐药的影响。

研究设计与样本

  • 先导性随机对照试验,纳入有梅毒史、无HIV感染的性活跃男男性行为者和跨性别女性52人,即日组(n=26)与延迟组(n=26)按1:1随机;所有人每日服用TDF/FTC共48周,即日组每日多西环素暴露前预防48周,延迟组自24周开始;主要结局为问卷测量的依从性与耐受性,性传播感染(衣原体、淋病、梅毒)发病为次要结局,并连续评估鼻腔金黄色葡萄球菌定植以监测多西环素耐药。

主要发现

  • 48周时即日组对延迟组自报依从性(≥95%):TDF/FTC为75.0%对66.7%(P=0.538),多西环素为70.8%对61.9%(P=0.526)。
  • 24周时即日组较延迟组任何性传播感染发病率降低;48周内使用多西环素(对比未使用,即延迟组前24周)与性传播感染减少相关(aOR 0.36;95%CI:0.15-0.89)。
  • 未发生多西环素暴露前预防相关严重不良事件;6人检出新发多西环素耐药金黄色葡萄球菌,其中即日组5人(P=0.077)。

关键数值与推荐

  • 自报依从性≥95%:即日组TDF/FTC 75.0%对延迟组66.7%(P=0.538),即日组多西环素70.8%对延迟组61.9%(P=0.526)。
  • 使用多西环素对比未使用与性传播感染减少相关:aOR 0.36;95%CI:0.15-0.89。
  • 新发多西环素耐药金黄色葡萄球菌:即日组5人对延迟组1人(P=0.077)。

临床怎么用

  • 作者认为双联HIV/多西环素暴露前预防可行且与性传播感染发病显著减少相关,并提出需进一步评估给药策略、疗效及对抗菌药物耐药的影响。

局限性

  • 原文结论指出需进一步评估给药策略、疗效及对抗菌药物耐药的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Men who have sex with men (MSM) and transgender women experience high sexually transmitted infection (STI) rates. This study evaluated the feasibility of doxycycline pre-exposure prophylaxis (doxyPrEP) for STI prevention in these key populations. METHODS: Sexually-active MSM and transgender women without human immunodeficiency virus (HIV) with prior syphilis were recruited. Participants initiated HIV PrEP with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) daily for 48 weeks and were randomized 1:1 to daily doxyPrEP for 48 weeks (immediate arm), or doxyPrEP initiated at 24 weeks (deferred arm). Primary outcomes included adherence, measured using questionnaires, along with tolerability; STI incidence (chlamydia, gonorrhea, syphilis) was a secondary outcome. Nasal carriage of Staphylococccus aureus was assessed serially for doxycycline resistance. RESULTS: Fifty-two participants were enrolled into the immediate (n = 26) and deferred (n = 26) arms. At 48 weeks, self-reported adherence (≥95%) was 75.0% versus 66.7% (P = .538) for TDF/FTC, and 70.8% versus 61.9% (P = .526) for doxycycline in the immediate versus deferred arms, respectively. No doxyPrEP-related serious adverse events occurred. Incidence of any STI at 24 weeks was reduced in the immediate versus deferred arms, and over 48 weeks, being on doxycycline (vs being off; ie, first 24 weeks of deferred arm) was associated with STI reduction (adjusted odds ratio [aOR] 0.36; 95% confidence interval [CI]: .15-.89). Emergent doxycycline-resistant S. aureus was identified in six individuals, with five in the immediate arm (P = .077). CONCLUSIONS: Dual HIV/doxyPrEP is feasible and associated with a significant reduction in incident STI. Further evaluation of dosing strategies, efficacy and impact on antimicrobial resistance is warranted.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Grennan T, Mohammed S, Edward J, et al. A Pilot, Randomized Controlled Trial of Dual Daily HIV and Sexually Transmitted Infection Pre-exposure Prophylaxis Using Tenofovir Disoproxil Fumarate/Emtricitabine and Doxycycline in Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women: The DuDHS Study. Clin Infect Dis. 2026. PMID: 39882974. doi:10.1093/cid/ciaf043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。